%20(1).png)
Asbestos litigation remains the clearest starting point for understanding how modern mass torts developed. What began as a series of isolated claims steadily evolved into a recurring liability exposure with broader legal and financial implications.
Many of the major waves, including tobacco, pharmaceuticals, and now PFAS-related claims, have followed a similar path: early scientific concern, plaintiff firm mobilization, consolidation through multi-district litigation (MDL) and eventually very large settlements.
For insurers, the key takeaway is that mass torts are not one-off events. They can build over decades and have a meaningful effect on reserves, pricing, and capital planning.
Asbestos as the Template for Future Mass Torts
Asbestos is widely considered the first true mass tort and remains one of the longest running in U.S. legal history.1 Although the health risks of asbestos exposure were documented in the 1920s, litigation accelerated decades later due to the latency period of diseases such as mesothelioma.
The 1973 Borel v. Fibreboard decision established that manufacturers could be held liable for failure to warn about latent health risks, fundamentally reshaping product liability law.2 Before decisions like Borel, product liability claims more often focused on manufacturing defects, obvious product failures, or negligence-based proof, rather than on a manufacturer’s duty to warn end users about concealed long-term health dangers associated with ordinary product use. This ruling triggered claims against manufacturers, distributors, and insurers. By the early 2000s:
- Hundreds of thousands of asbestos claims had been filed
- Thousands of corporate defendants were named
- Dozens of companies entered bankruptcy due to liability exposure
Equally important, asbestos litigation forced the legal system to develop the infrastructure that defines modern mass torts, including MDLs, aggregated settlements, and bankruptcy trust mechanisms.3 These tools became the template for future mass tort waves.
Second-Generation Mass Torts (1990s–2010s)
Following asbestos, mass tort litigation expanded into new domains, particularly pharmaceuticals, medical devices, and environmental exposure. This period also saw plaintiff aggregation and national litigation strategies become more established.
Tobacco Litigation
- The 1998 Master Settlement Agreement demonstrated that coordinated litigation against an entire industry could result in landmark settlements. It also validated the use of public health theories such as public nuisance, which would later reappear in opioid litigation.4
Pharmaceutical and Medical Device Litigation
- Major litigations involving Fen-Phen, Vioxx, and medical implants expanded failure-to-warn and design defect theories. These cases also illustrate how regulatory approval does not insulate companies from large-scale liability, particularly when post-market risk evidence emerges.
Environmental and Toxic Exposure
- Claims related to benzene, lead, and industrial contamination further broadened the scope of mass torts. Plaintiff firms that built expertise in asbestos litigation transitioned into these areas, creating a durable and scalable litigation model.
Current Landscape: Third-Generation Mass Torts (2015–Present)
The contemporary mass tort environment is more complex than previous waves. Opioid litigation (involving manufacturers, distributors, and pharmacies) represents one of the largest coordinated litigations in U.S. history5. To date, nationwide opioid-related settlements have exceeded $50 billion across manufacturers, distributors, and pharmacies.6 Similarly, talc and consumer product claims have demonstrated how legacy product exposure can evolve into large-scale litigation decades later.
Today’s mass torts scale faster than prior waves, driven by coordinated plaintiff strategies, advertising, and data-enabled claimant recruitment.
A defining characteristic of the current landscape is the speed of claim aggregation. Advertising, data analytics, and national plaintiff networks allow law firms to rapidly identify and recruit claimants thus accelerating the growth of litigation dockets compared to earlier mass tort eras.
The Next Wave of Mass Torts
Looking ahead, several emerging risk categories may develop characteristics associated with larger-scale mass tort activity.
- PFAS (“forever chemicals”) litigation is widely viewed as a potential successor to asbestos due to widespread environmental exposure, long-term health uncertainty, and multi-industry defendant involvement.7
- Nanoparticles and advanced materials.
- Pharmaceuticals and biologics including GLP-1 drugs.
- Environmental contamination and climate-related claims.
- Consumer products with latent health risk allegations.
- Social Media/Digital Privacy/AI.
These emerging torts share common risk markers: evolving science, regulatory scrutiny, long latency periods, and scalable plaintiff recruitment. For insurers and corporations, early identification of these patterns is critical, as the financial impact of mass torts often unfolds over multiple decades and can redefine liability cost structures across entire industries.
How Alan Gray Can Help
The long-tail and uncertain nature of mass tort exposure makes quantitative analysis essential for insurers seeking to manage reserve adequacy, aggregation risk, and emerging liability trends.
Alan Gray applies data-driven analytics that integrate claims, policy, and financial data with external litigation trends to provide a clearer view of complex mass tort exposures. For legacy and emerging liabilities such as asbestos, PFAS, and other long-tail risks, Alan Gray performs structured exposure analysis and future projections that help clients assess how claim frequency, severity, latency, and jurisdictional trends may impact ultimate losses, capital strain, and cash flow over time. This supports more informed reserving, pricing, and portfolio risk management decisions. Alan Gray’s quantitative services are particularly valuable in complex, multi-year mass tort environments, including:
- Exposure analysis for mass tort portfolios and emerging liabilities.
- Future loss projections and scenario modeling for reserving and capital planning.
- Allocation modeling across policy years, layers, and reinsurance structures.
- Data standardization & reconciliation of fragmented legacy claims and financial datasets.
- Cost and damage analysis for indemnity and defense spend trends.
Overall, this approach gives insurers and reinsurers a clearer view of tail risk, layer exhaustion, and long-term exposure, helping support reserving, settlement strategy, and broader management of evolving mass tort risk.
References
1. RAND. Asbestos Litigation. RAND Institute for Civil Justice, RAND Corporation, 2005. 2. Borel v. Fibreboard Paper Products Corp., 493 F.2d 1076 (5th Cir. 1973).
3. RAND. Asbestos Bankruptcy Trusts and Tort Compensation. RAND Institute for Civil Justice, RAND Corporation, 2010.
4. National Association of Attorneys General. Master Settlement Agreement with the Tobacco Industry. 1998.
5. Congressional Research Service. The Opioid Epidemic and Federal Efforts to Address It: Legal and Policy Developments. Congressional Research Service, 2022.
6. National Association of Attorneys General. National Opioid Settlements: Overview and Settlement Terms. National Association of Attorneys General, 2023.
7. Swiss Re Institute. Emerging Liability Risks: PFAS and Long-Tail Environmental Exposures. Swiss Re Institute, 2023.
